Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999–2023
Cancer Epidemiology · 2025
DOI: 10.1016/j.canep.2025.102960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Epidemiology, 2025. Verfasst von Natalie A Akoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD, United States. Electronic address: natalie.a.akoto@medstar.net. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Myelodysplastic syndromes (MDS) are bone marrow disorders that often affect older adults and can lead to acute myeloid leukemia (AML), a more aggressive cancer. While this progression is well known, national trends in AML-related deaths, specifically among patients with MDS, have not been well described. METHODS: Using CDC WONDER death certificate data from 1999 to 2023, we identified adults aged 25 years and above who died from AML with MDS listed as a contributing cause. We analyzed demographics, place of death, and trends over time. Age-adjusted mortality rates were calculated and stratified by sex, race, geography, and urbanization. We also examined national trends in AML incidence and mortality-to-incidence ratios (MIR). RESULTS: AML incidence was 5.8 per 100,000, rising slightly over time (AAPC + 0.5 %; 95 % CI: 0.25-0.70). Among 16,979 AML-related deaths in people with MDS, most were male (61.6 %), White (91.8 %), and aged ≥ 75 years. Nearly half died in hospitals, while < 1 % underwent autopsies. The age-adjusted mortality rate was 0.5 per 100,000 in males and 0.2 in females (p < 0.0001). Mortality declined overall (AAPC - 1.16 %; 95 % CI: - 1.75 to - 0.57), with the sharpest drop between 2021 and 2023 (APC - 17.12 %, 95 % CI: - 22.61 to - 9.20). Improvements were most notable in urban areas and among White patients. CONCLUSION: AML-related mortality in MDS patients has declined over the past 25 years, likely reflecting progress in treatment and supportive care. However, disparities persist. More equitable access to advanced therapies is needed to ensure all patients benefit from recent advances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, MD, United States. Electronic address: natalie.a.akoto@medstar.net.
- Department of Internal Medicine, Ascension Saint Agnes Hospital, United States.
- Johns Hopkins Bloomberg School of Public Health, United States.
- Department of Internal Medicine, MacNeal Hospital, United States.
- Johns Hopkins Bloomberg School of Public Health, United States; Johns Hopkins Carey Business School, United States.
Zitieren
APA
Akoto, N. A., Orhin, A. E., Chukwu, D. E., Gyato, A., Egyin, S., Idun, M. Y., & Aninkora, K. O. (2025). Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999–2023. Cancer Epidemiology. https://doi.org/10.1016/j.canep.2025.102960
Vancouver
Akoto NA, Orhin AE, Chukwu DE, Gyato A, Egyin S, Idun MY, et al. Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999–2023. Cancer Epidemiology. 2025. doi:10.1016/j.canep.2025.102960
BibTeX
@article{Akoto2025,
author = {Akoto, Natalie A and Orhin, Albert E and Chukwu, Denise Eke and Gyato, Albert and Egyin, Simon and Idun, Maame Yaa and Aninkora, Kwabena Owusu},
title = {Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999–2023},
journal = {Cancer Epidemiology},
year = {2025},
doi = {10.1016/j.canep.2025.102960}
}
EUVIMED